Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 1414 for allergen-induced late asthmatic response in mild allergic asthma
ISRCTN48047493Phase 3Completed
- Sponsor
- Memory Pharmaceuticals
- Start
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of MEM 1414 in allergic asthma and asthma (2 arms), sponsored by Memory Pharmaceuticals. Primary endpoint: Late asthmatic response after allergen challenge. Started Dec 2008; status: completed.
02
Drugs
MEM 1414
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on ISRCTN48047493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48047493.